- Home
- PATK vs ACAD Comparison
PATK vs ACAD Comparison
Compare PATK & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PATK
- ACAD
- Stock Information
- Founded
- PATK 1959
- ACAD 1993
- Country
- PATK United States
- ACAD United States
- Employees
- PATK N/A
- ACAD N/A
- Industry
- PATK Auto Parts:O.E.M.
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- PATK Consumer Discretionary
- ACAD Health Care
- Exchange
- PATK Nasdaq
- ACAD Nasdaq
- Market Cap
- PATK N/A
- ACAD 2.8B
- IPO Year
- PATK N/A
- ACAD 2004
- Fundamental
- Price
- PATK $83.90
- ACAD $17.07
- Analyst Decision
- PATK Strong Buy
- ACAD Buy
- Analyst Count
- PATK 9
- ACAD 17
- Target Price
- PATK $102.07
- ACAD $24.00
- AVG Volume (30 Days)
- PATK 379.7K
- ACAD 1.5M
- Earning Date
- PATK 05-01-2025
- ACAD 05-07-2025
- Dividend Yield
- PATK 2.28%
- ACAD N/A
- EPS Growth
- PATK N/A
- ACAD N/A
- EPS
- PATK 4.11
- ACAD 1.36
- Revenue
- PATK $3,715,683,000.00
- ACAD $957,797,000.00
- Revenue This Year
- PATK $8.30
- ACAD $13.07
- Revenue Next Year
- PATK $6.51
- ACAD $9.97
- P/E Ratio
- PATK $20.43
- ACAD $12.55
- Revenue Growth
- PATK 7.14
- ACAD 31.85
- 52 Week Low
- PATK $67.72
- ACAD $14.15
- 52 Week High
- PATK $98.90
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- PATK 39.60
- ACAD 41.84
- Support Level
- PATK $86.64
- ACAD $16.86
- Resistance Level
- PATK $88.39
- ACAD $17.31
- Average True Range (ATR)
- PATK 2.53
- ACAD 0.51
- MACD
- PATK 0.23
- ACAD 0.02
- Stochastic Oscillator
- PATK 28.57
- ACAD 43.24
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.